MedPath

Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery

Phase 1
Active, not recruiting
Conditions
Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resection
MedDRA version: 20.0Level: PTClassification code: 10018336Term: Glioblastoma Class: 100000004864
Therapeutic area: Phenomena and Processes [G] - Metabolism [G03]
Registration Number
CTIS2024-511171-15-00
Lead Sponsor
Celgene Corp.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Recruiting
Sex
All
Target Recruitment
216
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
Âİ Copyright 2025. All Rights Reserved by MedPath